Format

Send to

Choose Destination
Neurol Clin. 2020 Feb;38(1):65-94. doi: 10.1016/j.ncl.2019.08.003. Epub 2019 Nov 7.

Neuroimaging of Diseases Causing Dementia.

Author information

1
Nantz National Alzheimer Center, Houston Methodist Neurological Institute and Weill Medical College of Cornell University, 6560 Fannin Street, Scurlock 802, Houston, TX 77030, USA. Electronic address: jcmasdeu@houstonmethodist.org.

Abstract

Neuroimaging provides a window on the biological events underlying dementia. Amyloid PET is positive in Alzheimer disease (AD) and some cases of diffuse Lewy body disease, but negative in the frontotemporal dementias (FTDs). Tau PET using the current tracers shows the greatest signal in AD and a lesser signal in FTD. Quantifying volume loss with MRI and measuring metabolism with fluorodeoxyglucose PET helps separate different causes of dementia and follow their progression. Brain inflammation can be assessed with PET. Some of these techniques, still investigational, are likely to find their clinical niche in the near future.

KEYWORDS:

Alzheimer disease; Amyloid β; Neurodegeneration; Neuroimaging; PET; Tau

PMID:
31761062
DOI:
10.1016/j.ncl.2019.08.003

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center